Company Filing History:
Years Active: 2011
Title: **Christopher Lee Morton: Innovator in Carboxylesterase Inhibition**
Introduction
Christopher Lee Morton is an accomplished inventor based in Memphis, Tennessee. He has made significant contributions to the field of pharmaceuticals and pest control through his innovative research. Morton's work focuses on developing compounds that serve as carboxylesterase inhibitors, which have vital applications in medicine and agriculture.
Latest Patents
Christopher Lee Morton holds a patent for "Amide, aryl sulfonamide, aryl urea, and α,β-diketone derived carboxylesterase inhibitors, and their methods of use." This patent encompasses a range of compounds, including amides, aryl sulphonamides, aryl ureas, and α,β-diketones, which are useful as selective human intestinal carboxylesterase inhibitors and insect carboxylesterase inhibitors. The patent describes their potential in pharmaceutical compositions and pesticide formulations, highlighting methods to treat or mitigate the toxic effects following the administration of drugs, particularly cancer therapy drugs and drug overdoses. Furthermore, the compounds aim to enhance the effectiveness of insecticides and pesticides.
Career Highlights
Morton is currently affiliated with St. Jude Children's Research Hospital, where he engages in groundbreaking research that emphasizes not only innovation but also impact in the medical field. His work has fostered advancements in how certain drugs are utilized and improves safety protocols concerning drug administration.
Collaborations
Throughout his career, Christopher Lee Morton has collaborated with notable colleagues, including Philip Michael Potter and Janice Louise Hyatt. Working alongside these individuals has allowed him to expand his research capabilities and contribute to various projects that align with his innovative pursuits.
Conclusion
Christopher Lee Morton exemplifies innovation in the scientific community, particularly within the realms of pharmacology and pest management. His patent for carboxylesterase inhibitors reflects a commitment to improving human health and environmental safety. As he continues to work at St. Jude Children's Research Hospital, Morton's contributions will likely pave the way for future developments in these vital fields.